
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. is demonstrating a positive outlook due to significant advancements in its gene therapy offerings, particularly with the RMAT designation for detalimogene, which positions the therapy to capture considerable market share in community practice settings. The company’s clinical data indicates an improvement in complete response rates that align with best-in-class therapies while maintaining a superior overall profile due to the non-viral delivery method, which may enhance adoption across various treatment settings. Additionally, the increase in research and development expenses reflects a commitment to advancing pivotal studies like the LEGEND study, contributing to an optimistic assessment of the company's growth potential and an upward adjustment in valuation metrics.
Bears say
enGene Holdings Inc's stock faces a negative outlook due to disappointing performance of its product Detalimogene in the ongoing LEGEND trial, which has been marred by unexpected safety issues and changing regulatory requirements for approvals. Additionally, the emergence of unforeseen competition and a higher-than-expected capital requirement raise concerns about the company's ability to secure funding without significant equity dilution, potentially impacting share value. The critical complete response rates observed in preliminary cohorts are currently less competitive compared to peer products, emphasizing the company's vulnerability in a highly competitive biotechnology landscape.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares